y involve numerous risks and uncertainties, known and unknown, many of which are beyond Mirati's control. Such statements can usually be identified by the use of words such as "may", "would", "believe", "intend", "plan", "anticipate", "estimate" and other similar terminology, or state that certain actions, events or results "may" or "would" be taken, occur or be achieved. Forward-looking statements in this release include, but are not limited to, statements regarding the potential for accelerated approval path for MGCD265, ability to secure a partner for the mocetinostat program, and the ability to obtain an SPA from the FDA.
Whether actual results and developments will conform with our expectations and predictions is subject to a number of risks, assumptions and uncertainties, many of which are beyond our control, and the effects of which can be difficult to predict. These risks include those inherent in drug development, whether Mirati will be able to obtain financing when needed or on favorable terms, and other risks described in Mirati's filings with the Securities and Exchange Commission. In evaluating any forward-looking statements in this release, Mirati cautions readers not to place undue reliance on any forward-looking statements. Unless otherwise required by applicable securities laws, Mirati does not intend, nor does it undertake any obligation, to update or revise any forward-looking statements contained in this news release to reflect subsequent information, events, results or circumstances or otherwise.
Mirati Therapeutics, Inc.Consolidated Statements of Operations and Comprehensive Loss(In thousands except for share and per share amounts)
(Unaudited)Three months ended September 30,Nine months ended September 30,2013201220132012ExpensesResearch and development, net$
10,105General and administrative3,7101,7178,6164,019Total opera
Page: 1 2 3 4 5 Related medicine technology :1
|SOURCE Mirati Therapeutics, Inc.|
Copyright©2012 PR Newswire.
All rights reserved
. Mirati Therapeutics Prices Public Offering Of Common Stock2
. Sorrento Therapeutics Adopts Stockholder Rights Plan3
. Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 20134
. Shield Therapeutics Files Investigational New Drug Application for ST10 for the Treatment of Iron Deficiency in Chronic Kidney Disease5
. Cara Therapeutics Files Registration Statement for Proposed Initial Public Offering6
. Nektar Therapeutics Reports Financial Results for the Third Quarter of 20137
. Echo Therapeutics Announces Third Quarter 2013 Financial Results8
. Halozyme Therapeutics To Present At The Credit Suisse Healthcare Conference9
. Orexigen Therapeutics Enters Into Agreement with Sanofi to Manufacture Contrave for Territories Outside North America10
. PDL BioPharma Provides $70 Million in Financing to Durata Therapeutics11
. PTC Therapeutics to Present at Credit Suisse Annual Health Care Conference